title: Safety profile of the fluoroquinolones: focus on levofloxacin.
abstract: The fluoroquinolone class of antibacterial agents are among the most frequently prescribed drugs, with utility in a broad range of bacterial infections. Although very useful agents, the fluoroquinolones as a class are associated with a number of adverse events, some with considerable clinical significance. In the past 15-20 years, tolerability concerns have led to restrictions on the use of the fluoroquinolones and, in some instances, the withdrawal of agents from the market. This review focuses on the safety and tolerability of levofloxacin, a third-generation fluoroquinolone, relative to other fluoroquinolones. A literature search was performed of the MEDLINE database encompassing the dates 1980-2009, using as keywords the drug names levofloxacin and concurrently marketed fluoroquinolones combined with the words 'safety', 'adverse effect' or 'adverse drug reaction', or the name of the specific adverse effect. Adverse events commonly associated with the fluoroquinolones include gastrointestinal and CNS toxicity (most frequently headache and dizziness), as well as other adverse events including ECG abnormalities (for example QT interval prolongation), disrupted glucose metabolism, phototoxicity, tendon and joint disorders, hypersensitivity and skin disorders, and hepatic toxicity. Package inserts for the fluoroquinolones in Europe and the US contain warnings regarding these risks. US package inserts also carry 'black-box' warnings regarding the risk of tendon rupture and joint disorders with these agents; however, there is a substantial body of evidence to indicate that there are marked differences in the tolerability profiles of the individual agents within the fluoroquinolone class. These differences may be explained, at least in part, by structural differences: all fluoroquinolones share a basic quinolone core, with differences in specific side chains underlying the adverse event relationships. Furthermore, many of the fluoroquinolone-associated adverse effects and toxicities occur more frequently in patients with pre-existing risk factors, or in certain subpopulations. Notably, package inserts for the fluoroquinolones carry warnings regarding use in the elderly, paediatric patients and patients with pre-existing, or factors predisposing to, seizure disorders. Because of this, many adverse reactions with these agents could be prevented by improving patient screening and education. The recent withdrawal of gatifloxacin due to dysglycaemia makes it timely to review the safety and tolerability of the individual agents in this class. Overall, it appears that levofloxacin is relatively well tolerated, with low rates of clinically important adverse events such as CNS toxicity, cardiovascular toxicity and dysglycaemia.
authors.affiliation: Bryn Mawr Medical Specialists, Bryn Mawr, Pennsylvania, USA.
authors.forename: Hans H
authors.initials: HH
authors.lastname: Liu
mesh_terms: D000328:Adult; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002493:Central Nervous System Diseases / Q000139:chemically induced; D002648:Child; D017484:Dermatitis, Phototoxic / Q000209:etiology; D004342:Drug Hypersensitivity / Q000209:etiology; D004761:Enterocolitis, Pseudomembranous / Q000139:chemically induced; D005947:Glucose; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced
chemical_list: D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin; D005947:Glucose
references.citation: Infection. 2000 Jul-Aug;28(4):256-7
references.pmid: 10961538
references.citation: Drug Saf. 2007;30(8):705-13
references.pmid: 17696583
references.citation: Clin Pharmacol Ther. 2003 Apr;73(4):292-303
references.pmid: 12709719
references.citation: Curr Ther Res Clin Exp. 2003 Nov;64(9):646-61
references.pmid: 24944413
references.citation: J Antimicrob Chemother. 1994 Apr;33(4):685-706
references.pmid: 8056688
references.citation: Epidemiology. 1993 Nov;4(6):496-501
references.pmid: 8268277
references.citation: Ann Pharmacother. 2001 Oct;35(10):1194-8
references.pmid: 11675843
references.citation: Vet Pathol. 1990 May;27(3):162-70
references.pmid: 2353417
references.citation: BMJ. 2002 Jun 1;324(7349):1306-7
references.pmid: 12039823
references.citation: Antimicrob Agents Chemother. 1998 Jul;42(7):1831-6
references.pmid: 9661029
references.citation: Can J Infect Dis. 2002 Jan;13(1):54-61
references.pmid: 18159374
references.citation: Drug Saf. 2008;31(4):283-92
references.pmid: 18366239
references.citation: Am Fam Physician. 2002 Feb 1;65(3):455-64
references.pmid: 11858629
references.citation: Mol Pharmacol. 2001 Jan;59(1):122-6
references.pmid: 11125032
references.citation: Med Clin North Am. 2000 Nov;84(6):1447-69
references.pmid: 11155852
references.citation: Toxicol Lett. 2009 Jan 30;184(2):81-4
references.pmid: 19022360
references.citation: Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S113-9
references.pmid: 15942877
references.citation: Pharmacotherapy. 2007 Nov;27(11):1498-505
references.pmid: 17963459
references.citation: Ann Pharmacother. 2007 Nov;41(11):1859-66
references.pmid: 17911203
references.citation: Drugs. 1994 Apr;47(4):677-700
references.pmid: 7516863
references.citation: Drugs Aging. 2010 Mar 1;27(3):193-209
references.pmid: 20210367
references.citation: Curr Ther Res Clin Exp. 2004 May;65(3):225-38
references.pmid: 24764589
references.citation: Arch Intern Med. 1996 Jun 24;156(12):1327-32
references.pmid: 8651842
references.citation: Pediatr Infect Dis J. 2003 Dec;22(12):1128-32
references.pmid: 14688586
references.citation: Eur J Clin Pharmacol. 2009 Oct;65(10):959-62
references.pmid: 19707748
references.citation: Eur J Pharmacol. 2006 Dec 28;553(1-3):67-72
references.pmid: 17070519
references.citation: Pharmacotherapy. 2001 Mar;21(3):361-2
references.pmid: 11253862
references.citation: J Antimicrob Chemother. 2002 Apr;49(4):593-6
references.pmid: 11909831
references.citation: Drug Saf. 1996 Feb;14(2):69-77
references.pmid: 8852521
references.citation: J Antimicrob Chemother. 2000 May;45(5):557-9
references.pmid: 10797074
references.citation: Scand J Infect Dis. 2004;36(4):315-6
references.pmid: 15198194
references.citation: Pharmacotherapy. 2006 Jan;26(1):61-7
references.pmid: 16509027
references.citation: Eur J Pharmacol. 2004 Aug 16;497(1):111-7
references.pmid: 15321742
references.citation: Antimicrob Agents Chemother. 1993 Sep;37(9):1764-70
references.pmid: 7902066
references.citation: Clin Pharmacol Ther. 2000 Dec;68(6):658-66
references.pmid: 11180026
references.citation: Pharmacotherapy. 2001 Dec;21(12):1468-72
references.pmid: 11765299
references.citation: Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S144-57
references.pmid: 15942881
references.citation: Clin Infect Dis. 2003 Nov 1;37(9):1210-5
references.pmid: 14557966
references.citation: Chemotherapy. 2001;47 Suppl 3:3-8; discussion 44-8
references.pmid: 11549783
references.citation: N Engl J Med. 2005 Dec 8;353(23):2442-9
references.pmid: 16322602
references.citation: Pediatr Infect Dis J. 2002 Jun;21(6):525-9
references.pmid: 12182376
references.citation: J Pharmacol Exp Ther. 2001 Mar;296(3):806-10
references.pmid: 11181910
references.citation: South Med J. 1994 Sep;87(9):869-74
references.pmid: 8091248
references.citation: J Infect Chemother. 2003 Dec;9(4):314-20
references.pmid: 14691652
references.citation: J Cardiovasc Electrophysiol. 2004 Apr;15(4):475-95
references.pmid: 15090000
references.citation: Drugs. 1999;58 Suppl 2:1-5
references.pmid: 10553697
references.citation: Pediatrics. 2006 Sep;118(3):1287-92
references.pmid: 16951028
references.citation: Drug Saf. 2006;29(11):1087-100
references.pmid: 17061914
references.citation: Eur J Pharmacol. 2007 Nov 14;573(1-3):70-4
references.pmid: 17727838
references.citation: Clin Ther. 2008 Jan;30(1):152-7
references.pmid: 18343251
references.citation: Clin Infect Dis. 2002 Oct 15;35(Suppl 2):S191-9
references.pmid: 12353206
references.citation: South Med J. 2001 Aug;94(8):817-24
references.pmid: 11549195
references.citation: N Engl J Med. 2004 Mar 4;350(10):1013-22
references.pmid: 14999113
references.citation: Arch Dermatol. 2004 Dec;140(12):1537-8
references.pmid: 15611441
references.citation: Drug Saf. 2009;32(5):359-78
references.pmid: 19419232
references.citation: Eur Heart J. 2000 Aug;21(15):1216-31
references.pmid: 10924311
references.citation: Drugs. 1995;49 Suppl 2:16-28
references.pmid: 8549288
references.citation: J Clin Pharmacol. 2004 May;44(5):464-73
references.pmid: 15102866
references.citation: Heart. 2003 Nov;89(11):1363-72
references.pmid: 14594906
references.citation: Drug Saf. 2006;29(5):385-96
references.pmid: 16689555
references.citation: N Engl J Med. 1995 Dec 14;333(24):1600-7
references.pmid: 7477195
references.citation: Therapie. 1996 Jul-Aug;51(4):417-8
references.pmid: 8953820
references.citation: J Antimicrob Chemother. 2003 Sep;52(3):435-40
references.pmid: 12917247
references.citation: Am J Med. 2005 Mar;118(3):259-68
references.pmid: 15745724
references.citation: Drug Saf. 2003;26(2):109-20
references.pmid: 12534327
references.citation: Pharmacotherapy. 2005 Oct;25(10):1296-302
references.pmid: 16185172
references.citation: Rev Infect Dis. 1988 Jan-Feb;10 Suppl 1:S141-6
references.pmid: 3279489
references.citation: Clin Infect Dis. 2005 Nov 1;41(9):1254-60
references.pmid: 16206099
references.citation: Europace. 2007 Sep;9 Suppl 4:iv37-44
references.pmid: 17766322
references.citation: J Antimicrob Chemother. 2000 Nov;46(5):847-8
references.pmid: 11062213
references.citation: J Antimicrob Chemother. 1996 May;37 Suppl A:145-60
references.pmid: 8737134
references.citation: Int J Antimicrob Agents. 2007 Apr;29(4):374-9
references.pmid: 17241772
references.citation: Drug Saf. 2004;27(9):671-86
references.pmid: 15230648
references.citation: JAMA. 1993 Jun 2;269(21):2765-8
references.pmid: 8492403
references.citation: Pharmacol Ther. 1995 Jun;66(3):465-505
references.pmid: 7494856
references.citation: Epilepsia. 1993 May-Jun;34(3):453-68
references.pmid: 8504780
references.citation: Aliment Pharmacol Ther. 2006 Oct 15;24(8):1187-95
references.pmid: 17014577
references.citation: Arch Intern Med. 2000 Oct 9;160(18):2819-22
references.pmid: 11025792
references.citation: Clin Infect Dis. 2004 Mar 1;38(5):640-5
references.pmid: 14986246
references.citation: Ann Noninvasive Electrocardiol. 2006 Jan;11(1):52-6
references.pmid: 16472283
references.citation: South Med J. 2006 Jan;99(1):52-6
references.pmid: 16466123
references.citation: Fundam Appl Toxicol. 1988 Jul;11(1):110-9
references.pmid: 3209009
references.citation: J Antimicrob Chemother. 2006 Oct;58(4):891-4
references.pmid: 16880172
references.citation: J Infect Chemother. 2006 Apr;12(2):109-11
references.pmid: 16648952
references.citation: J Antimicrob Chemother. 1990 Nov;26 Suppl D:31-44
references.pmid: 2286589
references.citation: Eur J Pharmacol. 2000 Oct 20;406(3):341-3
references.pmid: 11040340
references.citation: Am Fam Physician. 2000 May 1;61(9):2741-8
references.pmid: 10821154
references.citation: Expert Opin Pharmacother. 2002 Sep;3(9):1251-66
references.pmid: 12186618
references.citation: J Chemother. 2006 Apr;18(2):127-39
references.pmid: 16736880
references.citation: Eur J Obstet Gynecol Reprod Biol. 2009 Apr;143(2):75-8
references.pmid: 19181435
references.citation: Chest. 2005 Nov;128(5):3398-406
references.pmid: 16304291
references.citation: Pharmacotherapy. 2005 Oct;25(10):1303-9
references.pmid: 16185173
references.citation: Arch Intern Med. 2003 Aug 11-25;163(15):1801-7
references.pmid: 12912715
references.citation: Clin Ther. 2004 Jul;26(7):940-50
references.pmid: 15336463
references.citation: N Engl J Med. 2006 Mar 30;354(13):1352-61
references.pmid: 16510739
references.citation: Am J Hematol. 2000 Jan;63(1):28-31
references.pmid: 10602164
references.citation: Drug Saf. 1999 Nov;21(5):407-21
references.pmid: 10554054
references.citation: Clin Infect Dis. 1999 Feb;28(2):352-64
references.pmid: 10064255
references.citation: Expert Opin Pharmacother. 2006 Apr;7(6):639-51
references.pmid: 16556082
references.citation: Br J Pharmacol. 2008 Aug;154(7):1538-43
references.pmid: 18500356
references.citation: Cell. 1995 Apr 21;81(2):299-307
references.pmid: 7736582
references.citation: Indian J Physiol Pharmacol. 1997 Apr;41(2):164-6
references.pmid: 9142563
references.citation: Am J Clin Dermatol. 2002;3(7):509-16
references.pmid: 12180900